Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : WFP and Takeda deepen partnership in West Africa to strengthen health emergency response This new initiative, which will run from 2022 to 2026, will build on existing activities as part of the current Takeda-WFP partnership

09/22/2021 | 03:47pm EDT

A new JPY 1.3 billion (approximately USD 10.8 million) contribution from Takeda Pharmaceutical Company Limited (Takeda) Global CSR Program to the World Food Programme (WFP) builds on previous successes and brings forward a 5-year initiative to help strengthen regional health supply chain capacities in West Africa.

Takeda and WFP’s existing partnership has focused onstrengtheningin-country public health supply chains and supportinglong-term pandemic preparedness, combining Takeda’s financial support with WFP’s supply chain knowledge and experience, built over nearly six decades of working in some of the most logistically challenging environments in the world.

In West Africa, fragile supply chains can lead to delays and damage in the transport and storage of medicines and other vital health items, leaving vulnerable communities without the help they need. This new initiative, which will run from 2022 to 2026, will build on existing activities as part of the current Takeda-WFP partnership, helpingto address supply chain gaps and challenges at a regional level, ensuring better accessibility and availability of health products in fragile environmentsthrough the WFP-managed United Nations Humanitarian Response Depot in Accra, Ghana.

The United Nations Humanitarian Response Depots (UNHRD) are a network of six strategically located hubs around the world that provide supply chain services to the humanitarian community.UNHRD Ghana, in Accra,supportshumanitarian organizations working across17 West African countries.This initiative will enhance the capacity of UNHRD Accra to store and deliver temperature-sensitive health products on behalf of the humanitarian community, and willcreate a Regional Logistics Knowledge Centre, where supply chain professionals and representatives from national governments in the region can receive training on best-in-class supply chain practices, ensuring that they are better equipped to face and manage health emergencies.

"WFP has been working with Takeda since 2020 and we value this partnership enormously," said WFP’s Executive Director David Beasley."This new generous donation from Takeda reflects the success and sustainability of our collaboration and will help public and private actors in West Africa prepare for, and respond to, health emergencies — so that vital supplies can reach those most in need."

"Takeda is proud to continue working with the World Food Programme totransform supply chains andensure access to critical health products inWest Africa," said TakakoOhyabu, Chief Global Corporate Affairs Officer at Takeda. "Our Global CSR Programpartners are selected annually by our employees around the world. Through this program, we arefocused on strengthening health systems andour work with WFPcontinues to be meaningful to employees. As we continue thispartnership, we hope to empower communities in West Africa to be ready forthe health challenges ofthe future."


Distributed by APO Group on behalf of World Food Programme (WFP).

© African Press Organization, source Press Releases

All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10:28aNOVAVAX : Dismisses Media Report on COVID-19 Vaccine Quality, Production Delays; Shares Do..
MT
10:23aNOVAVAX : Refutes Media Report on its COVID-19 Vaccine Quality, Production Delays
MT
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
10/18CALITHERA BIOSCIENCES : Buys Two Clinical-Stage Assets from Takeda to Boost Oncology Pipel..
MT
10/18Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from ..
CI
10/18Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
DJ
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
MT
10/13TR1 : Notification of Major Shareholding
DJ
10/13TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Expansion of Plasma Donation Cen..
BU
10/13Immusoft and Takeda Pharmaceutical Company Limited Collaborate to Discover and Develop ..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 391 B 29 648 M 29 648 M
Net income 2022 248 B 2 168 M 2 168 M
Net Debt 2022 3 258 B 28 484 M 28 484 M
P/E ratio 2022 20,8x
Yield 2022 5,55%
Capitalization 5 104 B 44 688 M 44 633 M
EV / Sales 2022 2,47x
EV / Sales 2023 2,33x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 246,00 JPY
Average target price 4 487,14 JPY
Spread / Average Target 38,2%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.56%43 985
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.12.25%235 986
ELI LILLY AND COMPANY43.51%219 674